GlucoTrack ( (GCTK) ) just unveiled an update.
Glucotrack, Inc. recently concluded a $10 million public offering and a concurrent private placement converting $4 million of outstanding debt into equity. The offering involved shares, pre-funded warrants, and series A and B common warrants, with proceeds earmarked for working capital and corporate purposes. The company aims to meet Nasdaq’s stockholders’ equity requirements, crucial for maintaining its listing. This strategic move highlights Glucotrack’s commitment to advancing its pioneering diabetes technologies while addressing financial compliance challenges.
Find detailed analytics on GCTK stock on TipRanks’ Stock Analysis page.
Trending Articles
- Deutsche Bank Pounds the Table on Tesla Stock
- ‘Breath of Fresh Air,’ Says Daniel Ives About Rivian Stock
- ‘It’s Not Too Late to Load Up,’ Says Analyst About Nvidia Stock
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
